Program
Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043
Also written as “SYS6043” and “SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection”.
Its studies are mostly in Fallopian Tube Neoplasms · Carcinoma, Hepatocellular · Neoplasms, led by 2 companies.
Drug pageAnti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSPC Pharmaceutical Groupits history only | 44 open or running | phase 3since Jun 15, 2026 | Feb 3, 2026 | Dec 30, 2027phase 2 · NCT07415863 |
| Conjupro Biotherapeuticsits history only | 11 open or running | phase 1since Feb 4, 2026 | Feb 4, 2026 | Dec 2029phase 1 · NCT07424547 |
- Named in CSPC Pharmaceutical Group’s own pipeline as
SYS6043
, phase 3, as of Aug 20, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 3, 2026First study: phase 2 study in Advanced/Metastatic Solid TumorsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07415863 · 820 planned · China
- Feb 4, 2026Conjupro Biotherapeutics’ first study: phase 1 study in NeoplasmsNew to Conjupro BiotherapeuticsConjupro Biotherapeutics · NCT07424547 · 386 planned · United States
- Jun 15, 2026Phase 3 study in Platinum-resistant Ovarian CancerPhase 3 reachedCSPC Pharmaceutical Group · NCT07708753 · 460 planned · China
- Jul 30, 2026Phase 2 study in Carcinoma, HepatocellularCSPC Pharmaceutical Group · NCT07761286 · 288 planned · China
- Sep 16, 2026Phase 2 study in Advanced Solid TumorsCSPC Pharmaceutical Group · NCT07833735 · 400 planned
Ahead
- Dec 30, 2027Primary completion: phase 2 study in Advanced/Metastatic Solid TumorsCSPC Pharmaceutical Group · NCT07415863
- Oct 15, 2028Primary completion: phase 2 study in Advanced Solid TumorsCSPC Pharmaceutical Group · NCT07833735
- Sep 30, 2029Primary completion: phase 2 study in Carcinoma, HepatocellularCSPC Pharmaceutical Group · NCT07761286
- Oct 1, 2029Primary completion: phase 3 study in Platinum-resistant Ovarian CancerCSPC Pharmaceutical Group · NCT07708753
TargetBeta
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) conjugated, via a cleavable linker, to a topoisomerase-1 inhibitor (TOP1i), with potential antineoplastic activity. Upon administration of anti-B7-H3/TOP1…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) ”NCIt, by rule
Other programs on CD276
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| risvutatug rezetecan | Hansoh Pharmaceutical Group | phase 3 | 30 |
| ifinatamab deruxtecan | Merck | phase 3 | 16 |
| tambotatug pelitecan | MediLink Therapeutics (Suzhou) | phase 3 | 13 |
| Anti-B7-H3 Antibody-drug Conjugate MHB088Crule | Minghui Pharmaceutical | phase 3 | 4 |
| Elfetabart Drozuntecanrule | BioNTech | phase 3 | 3 |
| Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101rule | tj-biopharma-co-ltd | phase 3 | 3 |
| Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01rule | radiopharm-theranostics-ltd | phase 2 | 1 |
| Autologous Anti-B7-H3 CAR T-cells BCB-276rule | brainchild-bio-inc | phase 2 | 1 |
| Anti-B7-H3/CD28 Bispecific Antibody XmAb808rule | Xencor | phase 1 | 2 |
| Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034rule | ideaya-biosciences | phase 1 | 1 |
| Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001rule | neok-bio-inc | phase 1 | 1 |
| HLX316 | Fosun Pharma | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07833735Advanced Solid Tumors | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Oct 15, 2028 | 400 |
| NCT07761286Carcinoma, Hepatocellular · China | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Sep 30, 2029 | 288 |
| NCT07708753Platinum-resistant Ovarian Cancer · China | 3 | Recruiting | CSPC Pharmaceutical Group | Oct 1, 2029 | 460 |
| NCT07424547Neoplasms · United States | 1 | Recruiting | Conjupro Biotherapeutics | Dec 2029 | 386 |
| NCT07415863Advanced/Metastatic Solid Tumors · China | 2 | Recruiting | CSPC Pharmaceutical Group | Dec 30, 2027 | 820 |
How it is read
Names in the registry
- “SYS6043”, 4 entries
- “SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection”, 1 entry
Conditions, from the studies’ own filings
- Fallopian Tube Neoplasms, 1 study
- Carcinoma, Hepatocellular, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.